RT Journal Article
SR Electronic
T1 Neutrophil extracellular traps linked to idiopathic pulmonary fibrosis severity and survival
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.24.24301742
DO 10.1101/2024.01.24.24301742
A1 Matson, Scott M.
A1 Ngo, Linh T.
A1 Sugawara, Yui
A1 Fernando, Veani
A1 Lugo, Claudia
A1 Azeem, Imaan
A1 Harrison, Alexis
A1 Alsup, Alex
A1 Nissen, Emily
A1 Koestler, Devin
A1 Washburn, Michael P.
A1 Rekowski, Michaella J.
A1 Wolters, Paul J.
A1 Lee, Joyce S.
A1 Solomon, Joshua J.
A1 Demoruelle, M. Kristen
YR 2024
UL http://medrxiv.org/content/early/2024/05/02/2024.01.24.24301742.abstract
AB Background Idiopathic pulmonary fibrosis (IPF) leads to progressive loss of lung function and mortality. Understanding mechanisms and markers of lung injury in IPF is paramount to improving outcomes for these patients. Despite the lack of systemic involvement in IPF, many analyses focus on identifying circulating prognostic markers. Using a proteomic discovery method followed by ELISA validation in multiple IPF lung compartments and cohorts we explored novel markers of IPF survival.Methods In our discovery analysis, agnostic label-free quantitative proteomics differentiated lung tissue protein expression based on survival trajectory (n=10). Following selection of the candidate pathway (neutrophil extracellular trap (NET) formation), we subsequently validated the presence of NETs in the IPF lung microenvironment using fully quantitative assays of known NET remnants in separate IPF cohorts (n=156 and n=52) with bronchoalveolar lavage fluid. We then assessed the correlation of these markers with baseline pulmonary function and survival.Results Discovery lung tissue proteomics identified NET formation as significantly associated with poor IPF survival. Using fully quantitative confirmatory tests for reproducibility we confirmed the presence of NET markers in IPF BALF and found significant correlations with worse pulmonary function in both cohorts (p<0.03 and p = 0.04 respectively). In the survival cohort, higher levels of NET markers predicted worse survival after adjusting for gender, age, and baseline physiologic severity (hazard ratio range: 1.79–2.19).Conclusions NET markers were associated with disease severity and worse survival in IPF. These findings suggest NET formation contributes to lung injury and decreased survival in IPF and may represent a potential therapeutic target.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by P20 GM130423 (SMM), R01 AR076450 and Pfizer ASPIRE Investigator Initiated Grant (WI227190) (MKD). The proteomics data were collected in the Mass Spectrometry and Proteomics Core facility utilizing the Orbitrap Ascend Tribrid System that was purchased with funds provided by the University of Kansas Cancer Center, which is supported by the National Cancer Institute Cancer Center Support Grant P30 CA168524 Author contributions: SMM, JJS, and MKD contributed to the study conception and design. KKB, PJW and JJS contributed to the recruitment of the study subjects. SMM, JSL, PJW, MKD, JJS, LTN, YS, VF, CL, IA, MPW, MJR, and MKD contributed to acquisition of the data. SMM, LN, AA, EN, DK and MKD contributed to the analysis and interpretation of the data. SMM and MKD contributed to the initial drafting of the manuscript. All authors contributed to critical revision and final approval of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University of Kansas Medical Center gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.